Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has announced a strategic partnership with Alpha Aesthetic Partners to launch the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. This initiative aims to generate real-world evidence regarding the integration of Obagi® saypha® MagIQ™, the company’s first FDA-approved injectable hyaluronic acid filler, in various clinical settings. Alpha Aesthetic Partners, known for its commitment to innovation and high-quality care models in aesthetic medicine, will spearhead a structured, multi-site evaluation of the new filler across its extensive network of practices.
The collaboration emphasizes the use of real-world data to enhance patient care and outcomes, as Alpha plans to collect standardized data from its practices. Initial findings from this evaluation are set to be shared at the upcoming Alpha Summit and other key industry conferences, showcasing the tangible impact of the injectable. John Wheeler, CEO of Alpha, highlighted the importance of understanding how skincare and injectables can achieve better results for both patients and practitioners.
Obagi Medical brings over 35 years of expertise in skincare, with a strong focus on addressing skin concerns such as hyperpigmentation and premature aging. The partnership with Alpha not only showcases Obagi's commitment to evidence-based aesthetic solutions but also aims to deepen the patient-provider relationship through comprehensive protocols and enhanced clinical performance.
Drew Fine, U.S. General Manager at Obagi, noted the significance of the collaboration in elevating patient care and integrating clinical excellence within a growing aesthetic landscape. This partnership is a significant step forward in the quest for innovation in the aesthetic medical field, promising to set new standards in patient experience and treatment outcomes.
MWN-AI** Analysis
The recent collaboration between Obagi Medical and Alpha Aesthetic Partners for the ALOHA Program represents a strategic move that could significantly bolster both companies' positions in the competitive aesthetics market. By leveraging real-world evidence, this initiative aims to enhance the adoption of Obagi’s saypha® MagIQ™ hyaluronic acid filler across Alpha’s extensive network, which is crucial in the evolving landscape of aesthetic treatments.
Investors should note that this partnership aligns well with broader trends towards data-driven decision-making in healthcare, particularly in aesthetics. The emphasis on real-world evidence to validate product efficacy and patient satisfaction positions both Obagi and Alpha as leaders at the intersection of innovation and clinical practice. Additionally, the three-dimensional matrix technology of Obagi’s filler could set it apart from competitors by delivering superior results, which could drive greater consumer demand.
The upcoming results from the ALOHA Program, to be shared at industry conferences, could serve as potential catalysts for stock movements, depending on the outcomes. Positive findings could not only strengthen Obagi’s market share but also reflect well on Waldencast plc, further solidifying its standing in the beauty and wellness sector.
For investors looking at Obagi, the collaboration hints at a robust growth trajectory, boosted by innovation and strategic partnerships. Additionally, Alpha's mission to simplify medical spa ownership indicates expanding operational efficiencies which could enhance profitability in the long term.
In conclusion, the Obagi-Alpha collaboration is a noteworthy development within the aesthetic industry. Investors should monitor initial findings from the ALOHA Program and consider the implications of enhanced product validation and market adoption on both companies' growth prospects.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and SACRAMENTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced that it has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program. Alpha was selected as an ALOHA launch partner for its demonstrated commitment to innovation, education, collaboration, and advancing aesthetic medicine through scalable, high-quality care models.
Through this real-world evaluation collaboration, Alpha will conduct a structured, multi-site evaluation of Obagi® saypha® MagIQ™ across its network of practices. The program will leverage Alpha’s strengths in systematic education, patient satisfaction, and cross-practice culture to generate real-world evidence demonstrating the value of integrating Obagi’s first FDA-approved injectable hyaluronic acid filler into diverse clinical environments.
“At Alpha, we’re focused on building capabilities and partnerships that meaningfully support our practices,” said John Wheeler, CEO of Alpha Aesthetics Partners. “What stood out about Obagi’s approach was the emphasis on real-world data and a thoughtful look at how skincare and injectables can work together to drive better outcomes for patients and providers.”
The ALOHA Program is designed to evaluate both clinical performance and patient experience, while supporting providers with complete Obagi protocols aimed at deepening patient relationships and driving consistent, high-quality outcomes. Standardized data will be collected across participating Alpha practices, with initial findings scheduled to be presented at the upcoming Alpha Summit. Results will also be shared at key industry conferences to highlight the real-world impact of introducing a new injectable across a leading network of aesthetic practices.
"Partnering with an innovative leader like Alpha underscores Obagi’s commitment to launching new aesthetics solutions grounded in meaningful real-world evidence,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA collaboration with Alpha brings together strong clinical leadership, operational excellence, and a shared focus on elevating patient care.”
Obagi® saypha® ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com/.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand’s website, https://www.obagi.com.
About Alpha Aesthetics Partners
?Founded in 2023, Alpha Aesthetics Partners aims to advance the medical aesthetics industry through best-in-class partner support and clinical training. With a vision to build the best operating and biggest network of medical aesthetics practices in the nation, Alpha Aesthetics Partners focuses on making medical spa ownership simpler and more collaborative, allowing partners to concentrate on providing world-class patient care. The company is a portfolio company of Thurston Group, with a rapidly growing presence across 31 locations in 12 states.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
- Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
- *Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does the partnership between Obagi Medical and Alpha Aesthetic Partners enhance the market position of Waldencast Acquisition Corp. WALD in New York and Sacramento's aesthetic medicine sectors?
What are the anticipated clinical outcomes from the ALOHA Program that may influence investor perceptions of Waldencast Acquisition Corp. WALD's growth in both New York and Sacramento?
How will the introduction of Obagi’s Hyaluronic Acid filler impact consumer demand for aesthetic treatments in New York and Sacramento, and what does this mean for Waldencast Acquisition Corp. WALD?
In what ways does the collaboration with Alpha Aesthetic Partners reflect Waldencast Acquisition Corp. WALD's commitment to innovation and leadership in the aesthetic industry across diverse markets like New York and Sacramento?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-4.69% G/L:
$1.525 Last:
13,064 Volume:
$1.51 Open:
